ClinicalTrials.gg

Program

Decitabine

Also written as “decitabine”, “decitabine (5-aza-2'deoxycytidine)” and “IV Decitabine”.

Its studies are mostly in Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Lymphoma, T-Cell, Peripheral · Leukemia, Myeloid, led by 9 companies.

Furthest: phase 4, since Nov 5, 200928 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai90 open or runningphase 4since Nov 5, 2009Nov 28, 2005none ahead
Otsuka82 open or runningphase 3since Aug 8, 2002Jul 19, 2002none ahead
EpiDestiny30 open or runningphase 1since Jan 31, 2019Jan 31, 2019none ahead
Johnson & Johnson30 open or runningphase 2since Aug 29, 2008Aug 29, 2008none ahead
AbbVie10 open or runningphase 3since May 3, 2019May 3, 2019none ahead
dong-wha-pharmaceutical-co-ltd10 open or runningphase 1since Sep 8, 2017Sep 8, 2017none ahead
Imunopharm Technology10 open or runningphase 1since May 14, 2018May 14, 2018none ahead
Sino Biopharmaceutical10 open or runningphase 4since Dec 9, 2013Dec 9, 2013none ahead
Treebough Therapies11 open or runningphase 1since May 20, 2025May 20, 2025Dec 30, 2026phase 1 · NCT07006025

Also a collaborator on its studies: dsm-firmenich.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Jul 19, 2002.

  1. Aug 5, 2010Phase 2 study in Pediatric Acute Myelogenous Leukemia (AML)Eisai · NCT01177540 · 25 enrolled · United States, Australia, Canada
  2. May 10, 2013Phase 2 study in Leukemia, Myeloid, AcuteJohnson & Johnson · NCT01853228 · 17 enrolled · Belgium, Denmark, France and more
  3. Dec 9, 2013Sino Biopharmaceutical's first study: phase 4 study in Myelodysplastic SyndromesNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT02013102 · 240 enrolled · China
  4. Mar 20, 2014Phase 2 study in Myelodysplastic SyndromesOtsuka · NCT02103478 · 130 enrolled · United States, Canada
  5. Sep 8, 2017dong-wha-pharmaceutical-co-ltd's first study: phase 1 study in Advanced Breast CancerNew to dong-wha-pharmaceutical-co-ltddong-wha-pharmaceutical-co-ltd · NCT03282825 · 18 enrolled · Korea, Republic of
  6. May 14, 2018Imunopharm Technology's first study: phase 1 study in NHLNew to Imunopharm TechnologyImunopharm Technology · NCT03535753 · 50 enrolled · China
  7. Jan 31, 2019EpiDestiny's first study: phase 1 study in HealthyNew to EpiDestinyEpiDestiny · NCT03828084 · 16 enrolled · United States
  8. May 3, 2019AbbVie's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT03941964 · 60 enrolled · United States
  9. Sep 10, 2019Phase 1 study in HealthyEpiDestiny · NCT04086238 · 46 enrolled · United States
  10. May 23, 2022Phase 1 study in Lymphoma, T-Cell, PeripheralOtsuka · NCT05403450 · 33 enrolled · United States, Australia, France and more
  11. Mar 31, 2023Phase 1 study in HealthyEpiDestiny · NCT05816356 · 10 enrolled · United States
  12. Apr 25, 2023Phase 3 study in Myelodysplastic SyndromesOtsuka · NCT05883956 · 13 enrolled · Australia, New Zealand
  13. Sep 22, 2023Phase 2 study in Myelodysplastic SyndromesOtsuka · NCT06091267 · 72 enrolled · China
  14. May 20, 2025Treebough Therapies's first study: phase 1 study in MDSNew to Treebough TherapiesTreebough Therapies · NCT07006025 · 20 planned · United States

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in MDSTreebough Therapies · NCT07006025

TargetBeta

“DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA inhibitor”ChEMBL 37, by rule

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07006025MDS · United States1RecruitingTreebough TherapiesDec 30, 202620
NCT06091267Myelodysplastic Syndromes · China2Active, not recruitingOtsukaMay 22, 202672
NCT05883956Myelodysplastic Syndromes · Australia, New Zealand3Active, not recruitingOtsukaDec 6, 202413
NCT05816356Healthy · United States1CompletedEpiDestinyJun 30, 202310
NCT05403450Lymphoma, T-Cell, Peripheral · United States, Australia, France and more1TerminatedOtsukaDec 16, 202433
NCT04086238Healthy · United States1CompletedEpiDestinyNov 21, 201946
NCT03941964Leukemia, Myeloid, Acute · United States3CompletedAbbVieMar 14, 202260
NCT03828084Healthy · United States1CompletedEpiDestinyMay 2, 201916
NCT03535753NHL · China1UNKNOWNImunopharm TechnologySep 1, 202050
NCT03282825Advanced Breast Cancer · Korea, Republic of1UNKNOWNdong-wha-pharmaceutical-co-ltdFeb 201818
NCT02103478Myelodysplastic Syndromes · United States, Canada2CompletedOtsukaJun 5, 2018130
NCT02013102Myelodysplastic Syndromes · China4UNKNOWNSino BiopharmaceuticalDec 2015240
NCT01853228Leukemia, Myeloid, Acute · Belgium, Denmark, France and more2TerminatedJohnson & JohnsonAug 28, 201717
NCT01177540Pediatric Acute Myelogenous Leukemia (AML) · United States, Australia, Canada2TerminatedEisaiJul 19, 201325
NCT01011283Myelodysplastic Syndromes · United States4TerminatedEisaiJan 201126
NCT00941109Myelodysplastic Syndromes · United States1CompletedEisaiSep 201112
NCT00796003Myelodysplastic Syndromes · Japan1CompletedJohnson & JohnsonOct 201039
NCT01378416Leukemia · United States1CompletedEisaiJan 200616
NCT00760084Leukemia, Myeloid, Acute · United States2CompletedEisaiSep 200510
NCT00744757Myelodysplastic Syndromes · Taiwan2CompletedJohnson & JohnsonSep 201037
NCT00619099Myelodysplastic Syndromes · United States2CompletedEisaiMar 201267
NCT00358644Leukemia, Myeloid, Acute · United States2CompletedEisaiFeb 200855
NCT00282399Myelodysplastic Syndromes · United States1TerminatedEisaiOct 200841
NCT00260065Myelodysplastic Syndromes · United States, Canada2CompletedEisaiJun 200899
NCT00043381Myelodysplastic Syndromes · United States3CompletedOtsukaNov 2002160
NCT00042016Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada2CompletedOtsuka40
NCT00042003Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada2CompletedOtsukaDec 200440
NCT00041990Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada2CompletedOtsuka40

How it is read

Names in the registry

  • “Decitabine”, 14 entries
  • “decitabine”, 8 entries
  • “decitabine (5-aza-2'deoxycytidine)”, 4 entries
  • “IV Decitabine”, 1 entry
  • “Decitabine + Cedazuridine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.